Best use of targeted agents for the treatment of advanced renal cell carcinoma

The advent of targeted therapies has substantially improved the prognosis of patients with metastatic renal cell carcinoma. Clinical outcomes can be optimised by patient education, close patient monitoring, appropriate dosing and prompt adverse event management by a multidisciplinary healthcare team.